The downgrade from Outperform to Market Perform by Leerink Partners suggests a less optimistic view on Regeneron's stock performance. The lowered price target from $1175 to $1077 indicates expectations of reduced future stock price appreciation, likely leading to a negative short-term impact on the stock price.